View in EDS HTML Full Text PDF Full Text

TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma.
Authors: Qiu, Dongbo1,2,3 (AUTHOR), Wang, Tiantian4 (AUTHOR), Xiong, Yi3 (AUTHOR), Li, Kun3 (AUTHOR), Qiu, Xiusheng1 (AUTHOR), Feng, Yuan5 (AUTHOR), Lian, Qinghai1 (AUTHOR), Qin, Yunfei3 (AUTHOR), Liu, Kunpeng6 (AUTHOR) liukp@gxu.edu.cn, Zhang, Qi2,3 (AUTHOR) zhangq27@mail.sysu.edu.cn, Jia, Changchang2,3 (AUTHOR) jiachch3@mail.sysu.edu.cn
Source: Oncogenesis. 9/12/2024, Vol. 13 Issue 1, p1-16. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21579024
DOI:10.1038/s41389-024-00534-1